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Background/aim: Increased bone turnover is a hallmark of hyperthyroidism. The underlying factors of how thyroid hormones affect
bone cells are still under the spotlight. Previous studies indicated serum osteoprotegerin (OPG), receptor activator of NF-kB ligand
(RANKL), and interleukin-6 (IL-6) as mediators of the effect of thyroid hormones on bone metabolism. Ultimately, the present research
aimed to examine the association of IL-6 with OPG and RANKL in patients with hyperthyroidism.
Materials and methods: We carried out this study with 39 newly diagnosed and untreated Graves’ patients and 43 healthy controls. In
addition to routine tests, we measured serum OPG, RANKL, and IL-6 levels.
Results: Mean age and sex distribution were similar in both groups. The hyperthyroid group had significantly higher OPG (p = 0.002)
and IL-6 (p < 0.001) levels, but RANKL levels were significantly lower in this group (p < 0.001). We found OPG not to correlate with
free T4 and T3, while it had a moderate and negative correlation with thyrotropin (TSH) (r = -0.372, p = 0.001). IL-6 had no correlation
with OPG but positively correlated with free T4 (r = 0.445, p < 0.001) and free T3 (r = 0.326, p = 0.035). It also negatively correlated with
RANKL (r = –0.247, p = 0.033).
Conclusion: Maintaining skeletal development and integrity is partially regulated by a normal balance of thyroid hormones. We
concluded that increases in serum OPG and IL-6 levels accompanied hyperthyroidism. However, excessive levels of the hormones might
cause drops in serum RANKL levels. Our results suggested that OPG, RANKL, and IL-6 might be involved in the cross-talking among
immunity, thyroid function, and bone metabolism in the case of hyperthyroidism.
Key words: Graves’ disease, osteoprotegerin, receptor activator of NF-kB ligand, interleukin-6, bone, immunity

1. Introduction
Graves’ disease (GD), a common autoimmune disorder,
is characterized by thyrotoxicosis, diffuse goiter, and
infiltrative ophthalmopathy [1]. The etiology and
pathogenesis of GD are not fully understood, but the role
of intrathyroidal thyrotropin receptor antibodies (TRAb)
is well known [2]. As TRAb is produced by immunological
mechanism, intrathyroidal inflammatory cells can secrete
proinflammatory cytokines to support local inflammation
and autoimmune process [3]. Interleukin-6 (IL-6) is
a significant pleiotropic proinflammatory cytokine
produced in various tissues such as bone, thyroid, and
blood mononuclear cells [4, 5]. These mononuclear cells
also express thyroid hormone receptors [6]. Lakatos et al.
showed that serum concentrations of IL-6 produced by
blood mononuclear cells in patients with toxic nodular
goiter or GD were significantly higher than in controls,
suggesting that IL-6 is involved in the pathogenesis of GD

[7]. In addition, Lv et al. revealed that IL-6 expression was
higher in thyroid tissue in elderly hyperthyroid patients
compared to the control group [8]. Although several
genetic studies have evaluated the association between
the IL-6 -174 G/C polymorphism and individuals’
susceptibility to GD, no consensus has been reached so far,
possibly due to study population differences and limited
sample sizes [9, 10].
Elevated thyroid hormones directly stimulate bone
cells, resulting in increased bone turnover [11]. Although
hyperthyroidism causes an increase in both bone formation
and resorption, the underlying mechanisms are still under
scrutiny. It was previously shown that the effects of thyroid
hormones on bone are mediated by osteotropic cytokines
such as IL-6 and IL-8 [12]. Osteoprotegerin (OPG) and
its cognate ligand, receptor activator of NF-kB ligand
(RANKL), mediate paracrine signaling between osteoblasts
and osteoclasts [13]. In general, upregulation of RANKL is
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associated with downregulation of OPG, and an increase
in the RANKL/OPG ratio favors osteoclastogenesis. OPG
is predominantly produced by osteoblasts and inhibits
RANKL-RANK interaction, leading to inhibition of
osteoclast development and osteoclastic bone resorption
[14]. OPG-deficient mice show intense osteoporosis
caused by enhanced adult stage osteoclastogenesis [14].
Because patients with cardiovascular and autoimmune
diseases have been reported to have elevated serum OPG
levels, it is likely to imply a possible relationship between
bone metabolism, vascular biology, and immune function
[15]. RANKL is considered to have the ability to mature
osteoclasts when macrophage colony stimulating factor
(M-CSF) is not present. Bone and lymphoid tissues are
where RANKL mRNA is mainly expressed. Eventually,
disruption of the balance of RANKL and OPG can lead
to undesirable bone resorption [16]. This system is also
affected by factors such as cytokines (including TNFalpha, IL-1), glucocorticoids, parathyroid hormone
(PTH), estrogen, and vitamin D [17].
The literature trying to correlate thyroid hormones
and bone metabolism indicates that tri-iodothyronine
(T3) stimulates osteoblast proliferation by increasing the
expression of osteocalcin, alkaline phosphatase (ALP),
type 1 collagen and insulin-like growth factor-I [18].
Several other studies have examined the effect of thyroid
hormones on serum IL-6 and its relationship to bone loss
[19]. IL-6 can exert its inhibitory effect on bone formation
in two ways: a direct effect through gp130-STAT 1/3
signaling or an indirect effect by manipulating the balance
between OPG and RANK and its ligand (RANKL) [20].
In vitro studies on organ cultures of fetal rat limb and
neonatal mouse calvariae also showed an unmediated
stimulation of bone resorption by T3 [21]. Miura et al.
revealed that mRNA expression of RANKL in bone was
enhanced by T3 [22]. Nonetheless, some other studies
found how T3 stimulates osteoclastogenesis was divergent
when compared to RANKL. Kanatanı et al. concluded
that OPG did not inhibit T3-induced osteoclast-like cell
development from osteoclast precursor cells, while it
completely inhibited their formation, induced by RANKL
and M-CSF [23]. Suda et al. discovered T3 not to influence
IL-6 concentrations and prostaglandin E2, known to
upregulate RANKL expression in osteoblast/stromal cells.
This result supports that the primary regulator in T3induced osteoclast differentiation may not be the RANKL/
OPG system [24]. Based on these contradictory results, the
present study aimed to investigate the relationship between
IL-6, which is a part of immunity, and OPG and RANKL,
which are involved in bone metabolism in patients with
hyperthyroidism.

2. Materials and methods
2.1. Study protocol
It was a cross-sectional study and included newly
diagnosed and untreated GD patients (n = 39) and
euthyroid healthy subjects with no thyroiditis or any other
acute or chronic diseases (n = 43). The participants were
aged between 18-65 and selected among those visiting the
endocrinology outpatient clinics of Ankara Training and
Research Hospital, Turkey.
The diagnosis of Graves’ disease was confirmed by
the presence conventional symptoms of hyperthyroidism,
biochemically overt hyperthyroidism, enlarged thyroid
gland and increased blood supply on ultrasound,
anti-thyroid peroxidase antibody (anti-TPO) or antithyroglobulin antibody (anti-Tg) positivity, TRAb
positivity in all patients, and increased radioactive iodine
uptake in thyroid scintigraphy. Some patients also had
ophthalmopathies at the time of diagnosis.
The inclusion criteria were as follows: (i) no acute
or chronic diseases (recent infection/inflammation,
chronic obstructive pulmonary disease, autoimmune
diseases, malignancy, chronic renal or liver failure, and
heart failure) besides hyperthyroidism, (ii) no medicine
treatment affecting either the immune system or bone
metabolism within a year before the enrollment, (iii) no
pregnancy within the last 18 months before enrolment;
(iv) no medical treatment for hyperthyroidism, (v) no risk
factors for an altered bone turnover (connective tissue
disorders, immobilization, malabsorption, history of
bone fracture within the last 12 months), (vi) no history
of thyroid operation or prior exposure to radioiodine or
external radiation.
We measured some parameters of the participants’
blood samples: serum levels of free-thyroxine (free
T4), free T3, thyrotropin (TSH), TRAb (except control
group), anti-Tg, calcium (Ca), anti-TPO, magnesium
(Mg), phosphorus (P), PTH, serum 25-hydroxyvitamin D
(25(OH)D), OPG, RANKL, and IL-6.
We obtained venous blood samples following
overnight fasting from the antecubital vein between 9:00
and 11:00 a.m. at a resting position. We centrifuged the
samples at 1500 g for 10 min. We aliquoted separated
sera were into Eppendorf tubes and stored them at -80 °C
till the analyses. As a part of their clinical evaluation, we
sought demographic and clinical data from the subjects.
We matched the patients with the healthy controls by age
and sex. We performed radioactive iodine uptakes, thyroid
ultrasonography, and scintigraphy to diagnose GD.
Ankara Numune Training and Research Hospital
Ethical Committee granted the relevant approval for our
study protocol (Number: 2300/2018). We obtained written
informed consent from each participant and carried out
the research following the principles of the Declaration of
Helsinki.
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2.2. Laboratory analysis
We measured serum levels of free T3, free T4, TSH, antiTg, and anti-TPO using Beckman Coluter Inc. (CA, USA)
DxI 800 Analyzer with a two-site immunoenzymatic assay,
according to the manufacturer’s instructions. Serum TRAb
was tested using Siemens Healthcare GmbH (Erlangen,
Germany) Immulite 2000 immunoassay analyzer following
the automated sandwich chemiluminescent immunoassay
method. We detected serum IL-6 levels with Beckman
Coulter Access 2 autoanalyzer with simultaneous one-step
immunoenzymatic assay.
We determined serum OPG and RANKL levels with
commercial human ELISA (quantitative double antibody
sandwich ELISA method) test Kit (My Biosource Inc.
CA, USA) according to the manufacturer’s protocol. For
OPG, the detection range of the kit was between 62.5 and
4000 pg/mL , and the assay sensitivity was 2 pg/mL. For
RANKL, the measurement range of the kit was between
15–240 pmol/L, and the assay sensitivity was 1 pmol/L. For
both parameters intraassay precision was <8% and interassay precision was <12%.
2.3. Statistical analysis
We run all statistical analyses of the data on the Statistical
Package for Social Sciences (SPSS) program version 21.0
for Windows (SPSS Inc., Chicago, IL). The Kolmogorov–
Smirnov test was performed to check the normality of
distribution of the data. We showed normally distributed
continuous and categorical values as mean±SD and
numbers and percentages, respectively. Using the ChiSquare test, we explored the differences between the
groups by the categorical variables. We expressed
non-normally distributed parameters as medians with
interquartile range [IQR]. We compared the groups by
continuous variables utilizing the Student’s t-test or Mann–
Whitney U test. We calculated Pearson’s or Spearman’s
rank correlation coefficient to examine the correlations
of the study variables. We considered differences to be
statistically significant when p < 0.05. The trial had over
94% power for OPG and RANKL calculated with the
G*Power program [25].
3. Results
Thirty-nine newly diagnosed graves patients (28 female, 11
male) and forty-three healthy controls (33 female, 10 male)
participated in the study. Mean age and sex distribution
were similar in both groups. Table 1 presents the baseline
characteristics of the participants. Although the groups did
not differ by 25(OH)D (p = 0.45), Ca (p = 0.80), and Mg
(p = 0.73), there were significant differences between them
by PTH, P, and ALP levels (p < 0.001). PTH and P levels
were lower in GD patients. The hyperthyroid patients had
significantly lower TSH (p < 0.001) and higher free T4 and
free T3 concentrations than control cases (p < 0.001 for
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free T4; p < 0.001 for free T3). We measured anti-TPO
and anti-Tg autoantibodies for both groups, but TRAb
was only measured in the patient group and the median of
TRAb was 29.9 (IQR = 56.1). The groups also significantly
differed by the anti-TPO and anti-Tg levels (p < 0.001 for
anti-TPO and p = 0.03 for anti-Tg).
OPG (p = 0.002) and IL-6 (p < 0.001) were significantly
higher in the patient group, which had significantly lower
RANKL (p < 0.001). OPG showed a weak and positive
correlation with ALP (r = 0.264, p = 0.018) but a negative
one with TSH (r = -0.372, p = 0.001). We found no
correlation between OPG and other study parameters.
There were positive correlations between RANKL levels
and TSH (r = 0.493, p < 0.001), PTH (r = 0.291, p = 0.01),
P (r = 0.508, p < 0.001), but negative correlations between
RANKL and IL-6 (r = -0.247, p = 0.03), free T3 (r = -0.386,
p = 0.01), free T4 (r = -0.485, p < 0.001), anti-TPO (r =
-0.343, p = 0.003). IL-6 had no correlation with OPG but
positively correlated with free T4 (r = 0.445, p < 0.001),
free T3 (r = 0.326, p = 0.035), anti-TPO (r = 0.337, p =
0.007), and ALP (r = 0.426, p < 0.001). It also negatively
correlated with RANKL (r = -0.247, p = 0.033), P (r =
-0.347, p = 0.002), PTH (r = 0.322, p = 0.006), and TSH
(r = -0.488, p < 0.001). Table 2 demonstrates the results
of the correlation analyses with all participants. When
correlation analysis was performed only with the results
of graves patients, OPG was not correlated with any test.
RANKL was only negatively correlated with free T4 (r =
-0.334, p = 0.038), and IL- 6 was only positively correlated
with ALP (r = 0.441, p = 0.06).
4. Discussion
As a result, we discovered hyperthyroid patients had
elevated serum OPG and IL-6 levels and lowered RANKL
concentrations compared to the healthy controls. These
increases were associated with the entity of thyroid
dysfunction and an increase in bone turnover. We found
OPG not to correlate with free T4 and T3, while it had a
moderate and negative correlation with TSH. IL-6 had no
correlation with OPG but positively correlated with free
T4 and free T3. It also negatively correlated with TSH and
RANKL. Also RANKL was positively correlated with TSH
but negatively correlated with free thyoid hormones.
It is well-known that the increase in thyroid hormones
affects bone structure and strength and eventually causes
bone loss. Nevertheless, the underlying mechanism of how
thyroid hormone functions on bone loss is still undercover.
The bone cycle falls to nearly half of its standard turnover
time (3–4 months) in the case of hyperthyroidism. Such
an accelerated rate of turnover generates an increased
number of osteoclast resorption sites and ultimately boosts
bone resorption ratio, causing osteoporosis and fragility
fracture.
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Table 1. Baseline characteristics of the participants.
Graves patients (n = 39)

Controls (n = 43)

p value

Age (years)a

40.03 ± 11.28

37.84 ± 7.31

0.29

TSH (mIU/L)a

0.02 ± 0.03

1.95 ± 1.14

<0.01

Free T4 (ng/dL)a

4.33 ± 2.07

0.98 ± 0.21

<0.01

Free T3 (ng/L)a

16.14 ± 8.55

3.36 ± 0.41

<0.01

Anti-TPO (IU/mL)b

81.1 (259.5)

3.65 (15.72)

<0.01

ALT (U/L)a

30.23 ± 17.46

20.53 ± 14.22

<0.01

AST (U/L)a

24.38 ± 12.13

20.09 ± 5.85

0.07

ALP (U/L)b

83.0 (65.5)

58.0 (29.0)

<0.01

GGT (U/L)b

29.0 (26.0)

13.0 (13.0)

<0.01

Ca (mg/dL)a

9.39 ± 0.54

9.37 ± 0.43

0.80

P (mg/dL)b

1.80 (0.25)

3.16 (1.41)

<0.01

Mg (mmol/L)a

4.07 ± 1.19

3.99 ± 0.59

0,73

PTH (pg/mL)b

23.3 (16.75)

50.4 (25.4)

<0.01

25(OH)D (µg/L)b

11.28 (7.49)

10.35 (9.80)

0.45

OPG(pg/mL)a

887.07 ± 342.61

658.26 ± 301.01

<0.01

RANKL (pmol/L)a

34.09 ± 11.57

54.07 ± 18.35

<0.01

IL-6 (pg/mL)b

3.58 (6.19)

1.44 (1.18)

<0.01

RANKL/OPGb

0.04 (0.03)

0.08 (0.11)

<0.01

a: Mean ± standard deviation.
b: Median (interquartile range).
p: val<0.05 denoted as statistically significant (in bold).
*Student’s t-test; Mann–Whitney U test.
Abbreviations:TSH, Thyrotropin; free T4, free thyroxine; free T3, free triiodothyronine; Anti-TPO,
Anti-thyroid peroxidase antibody; ALT, alanine aminotransferase; AST, aspartate aminotransferase;
ALP, alkaline phosphatase; GGT, gamma-glutamyl transferase; Ca, calcium; P, phosphorus; Mg,
magnesium; PTH, parathormone; 25(OH)D, 25 hydroxy vitamin D; OPG, osteoprotegerin; RANKL,
receptor activator of NF-kB ligand; IL-6, serum interleukin 6; RANKL/OPG, RANKL/OPG ratio;
TRAb, thyrotropin receptor antibodies.

Previously, few studies attempted to examine OPG in
thyroid dysfunction, and these studies reported inconsistent
results. Nagasaki et al. showed that serum OPG levels
in hypothyroid patients were significantly higher than
normal controls [26]. It has, therefore, been suggested that
by acting as an inhibitor of osteoclastogenesis, OPG may
establish a link between hypothyroidism and a reduction
in bone resorption. OPG levels in overt thyrotoxicosis were
evaluated in several trials; however, the mechanism of how
thyroid hormone dysfunctions modify serum OPG has not
exactly yet been revealed. Besides, thyrotoxicosis, which is
known to be associated with osteoclastogenesis, is predicted
to be associated with decreased OPG levels. However,
Amato et al. showed that serum OPG concentrations were
higher in hyperthyroid patients than in euthyroid subjects
[27]. Mochizuki et al. demonstrated that taking antithyroid drugs significantly reduced serum OPG levels [28].

Similarly, we observed that serum OPG concentrations
were increased in hyperthyroid patients compared to
euthyroid subjects, regardless of age. This finding was
also consistent with other data suggesting that thyroid
hormones have physiological effects on OPG production.
Varga et al. revealed that thyroid hormone promoted OPG
mRNA levels in mature MC3T3-E1 osteoblastic cells but
not in bone marrow stromal ST2 cells or preosteoblastic
MC3T3-E1 cells [29]. In addition, previous studies have
shown that OPG and RANKL are produced by thyroid
follicular cells and OPG mRNA is regulated by TSH and
cytokines [30]. Hofbauer et al. determined that OPG
mRNA levels were three times higher in thyroid surgery
specimens from Graves’ patients, whereas Lv et al.
demonstrated increased IL-6 expression in hyperthyroid
tissue, which indicates the possible effect of autoimmunity
[8, 30]. Weetmann et al. found that IL-6 increased
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Table 2. Correlation table for all participants.
Parameters

OPG

RANKL

IL-6

r value

p value

r value

p value

r value

p value

Age (years)

–0.095

0.397

–0.107

0.339

0.226

0.052

Ca (mg/dL)

0.097

0.387

0.100

0.373

–0.001

0.996

P (mg/dL)

–0.197

0.077

.508**

<0.001

–.347**

0.002

Mg (mmol/L)

0.130

0.258

–0.018

0.876

–0.131

0.267

ALP (U/L)

.264*

0.018

–0.099

0.383

.426**

<0.001

PTH (pg/mL)

–0.135

0.239

.291

0.010

–.322

0.006

25(OH)D (µg/L)

0.033

0.769

–0.104

0.356

0.040

0.735

TSH (µIU/mL)

**

–.372

0.001

.493

<0.001

–.488

<0.001

Free T3 (ng/L)

–0.037

0.813

–.386**

0.010

.326*

0.035

Free T4 (ng/dL)

0.209

0.060

–.485

<0.001

.445

<0.001

Anti-TPO (IU/mL)

0.199

0.097

**

–.343

Anti-Tg(IU/mL)

–0.093

0.614

–0.182

TRAb (U/L)

–0.035

0.834

OPG (pg/ml)

1

RANKL (pmol/l)

–0.162

0.146

1

IL-6 (pg/ml)

0.221

0.056

–.247*

0.033

1

RANKL/OPG

–.781**

<0.001

.684**

<0.001

–.363**

**

**

**

**

**

**

0.003

**

.337

0.007

0.319

0.151

0.419

0.218

0.189

0.024

0.887

–0.162

0.146

0.221

0.056

–.247

*

0.033
0.001

**Significant at the 0.01 level (2-tailed).
*Significant at the 0.05 level (2-tailed).
r: Correlation coefficient; Pearson’s correlation coefficient (normal distribution) and
Spearman’s rank coefficient (not normal distribution).
Abbreviations: Ca, calcium; P, phosphorus; Mg, magnesium; ALP, alkaline phosphatase
PTH, parathormone; 25(OH)D, 25 hydroxy vitamin D; TSH, thyrotropin; free T3, free
triiodothyronine; free T4, free thyroxine; Anti-TPO, Anti-thyroid peroxidase antibody;
Anti-Tg, Anti-thyroglobulin antibody; TRAb, thyrotropin receptor antibodies;OPG,
osteoprotegerin; RANKL, receptor activator of NF-kB ligand; IL-6, serum interleukin 6.
intrathyroidally in GD, but not in serum [4]. In this case,
our study confirms that serum IL-6 is not only increased by
blood mononuclear cells and bone in hyperthyroid patients
but also produced by the thyroid tissue in association with
OPG. This proposition suggests that the increase in OPG in
both hypothyroid and hyperthyroid patients may be due to
the significant effect of IL-6 and autoimmunity.
Our statistical analyses revealed that serum OPG levels
did not correlate with free T3 or free T4. Nevertheless,
Mochizuk et al. found it to correlate with free T4 but not
with free T3, while Amato et al. showed a correlation of
OPG levels with free T3 but not with free T4 [27, 28]. Our
findings also revealed that OPG levels negatively correlated
with TSH levels, as opposed to the conclusions from
Özdemir et al., suggesting that thyroid hormone status
might affect OPG [31]. Besides, TRAb is known to be used
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to diagnose GD and interacts with and stimulates the TSH
receptor expressed in specific tissues. However, we did not
establish any correlation between OPG and TRAb.
Since some studies have shown that TSH has
inhibitory effects on skeletal remodeling independent of
thyroid hormone , it can be argued that TRAb or TSAb
have an inhibitory role in bone metabolism [32]. These
observations are consistent with the hypothesis that
bone metabolism is regulated by TSH through different
mechanisms independent of the RANKL-OPG pathways
[30]. Abe et al. showed that TSH has a critical role in
maintaining bone mass independent of thyroid hormones.
In their study, osteoporosis was increased in TSH receptor
(-/-) knockout mice. They speculated that the skeletal loss
that occurs in hyperthyroidism is due to low TSH levels, as
opposed to simply increased thyroid hormones [33].

OMMA et al. / Turk J Med Sci
It is known that thyrotropin receptor (TSHR) is
expressed in osteoclasts and osteoblasts [34]. In one study,
intermittent low-dose TSH treatment was shown to prevent
ovariectomy-induced bone loss in mice. In another study,
OPG transcription was significantly increased in response
to TSH [34]. TSH can also trigger the expression of type 2
iodothyronine deiodinase in osteoblasts. Therefore, as in
hyperthyroidism, suppressed TSH levels can cause bone
loss. However, the main view on this subject is that TSH is
a direct negative regulator of bone turnover. Although the
effects of agonist TRAb on the skeleton are still unknown,
it is more likely that these antibodies bind to and mobilize
the skeletal TSHR. There is a study that supports this
concept, showing an inverse association of bone density
loss with TRAb levels.
IL-6 is one of the major proinflammatory cytokines
whose serum levels are known to be elevated in GD [35].
IL-6 can enhance the development and production of
thyroid receptor antibodies during the GD course [36].
In this context, Grubeck-Loebenstein et al. showed that
there are follicular cells synthesizing IL-6 in the thyroid
glands of GD patients [37]. Although evidence to date
indicates that IL-6 is critical in the early phase of osteoclast
differentiation, IL-6 has not been found to mediate the
effect of T3 on osteoclast differentiation [37]. In addition,
it was previously revealed that IL-6 reinforced RANKL
mRNA expression and hindered bone formation [20]. In
our study, the hyperthyroid group had significantly higher
IL-6 levels than the controls.
Although the literature shows conflicting results on
IL-6 levels regarding thyroid status, we found that IL-6 was
strongly and negatively correlated with TSH but positively
correlated with free T3 and free T4. IL-6 correlated
positively with anti-TPO and ALP, while negatively
correlated with RANKL, P and PTH. Although IL-6 is
secreted from normal parathyroid tissue and with PTH in
hyperparathyroidism, the negative correlation of IL-6 with
PTH in our study can be explained by slight increases in
Ca levels [38].
In our study, an increase in favor of hyperthyroidism
was found in ALP. Although the groups did not differ
in terms of Ca, Mg and 25(OH)D, PTH was lower in
hyperthyroid patients. In vitro, PTH is known to inhibit
OPG mRNA expression in cultured bone marrow [39].
Serum OPG levels also have a negative relationship with
PTH in healthy men over 40 years. Increased serum Ca
caused by increased mobilization of bone minerals in
hyperthyroid patients suppresses serum PTH levels. The
multiple regression analysis by Mochizuki et al. resulted
in OPG having an independent, significant, and negative
correlation with PTH, but it was not the case with Ca and
P, which indicates that PTH is a remarkable predictor of

OPG during thyrotoxicosis treatment [28]. Nonetheless,
we could not reach any correlation between OPG and
PTH, Ca, P, and 25(OH)D. Although we did not measure
it in our study, 1,25-dihydroxyvitamin D (1,25-(OH)2D)
inhibits T3-induced expression of OPG mRNA, but low
levels of 1,25-(OH)2D in hyperthyroidism are likely to
explain the high OPG levels in GD patients [27, 29]. We
can say that elevated serum OPG levels mean a stabilizing
mechanism against higher bone resorption caused by
hyperthyroidism
On the other hand, there is also evidence that there
is no relationship between thyroid status and OPG and
RANKL levels. Giusti et al. showed that patients with
different thyroid hormone levels and levothyroxine doses
had similar OPG and RANKL levels [40]. In another
study, it was demonstrated that recombinant TSH did
not affect OPG and RANKL levels in differentiated
thyroid carcinoma [41]. It has been shown that T3 has
a direct effect on the proliferation and differentiation of
human osteoblast-like cells, and T3 is unable to stimulate
osteoclastic bone resorption in the absence of osteoblasts
[42]. Kanatani et al. revealed that although T3 increased
OPG mRNA expression in bone cells, it had no effect on
RANKL mRNA expression [23]. These results imply that
the RANKL/OPG system is not a major regulator of T3induced osteoclast differentiation.
The present study had a strength, as well as some
limitations. Its primary strength was related to the
homogeneity of the patient groups included. Regarding
the limitations, we designed the study to be cross-sectional
with no follow-up data and post-treatment results of the
study groups. Also, the sample size was relatively small.
In conclusion, we found that the regular balance of
thyroid hormones could regulate skeletal development and
help the preservation of skeletal integrity. Our study showed
that hyperthyroidism was associated with an elevation in
serum OPG and IL-6 levels while a decrease in serum
RANKL in relation to the excess in thyroid hormones. The
results revealed that IL-6 had an important function in
the stimulation of the RANKL-RANK/OPG mechanism,
which was strongly enhanced when the presence of
accelerated bone turnover such as thyrotoxicosis. Finally,
OPG, RANKL, and IL-6 might be involved in the crosstalking among immunity, thyroid function, and bone
metabolism in the case of hyperthyroidism. Further and
more studies will help elucidate this proposition.
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